Oxcarbazepine Oral Suspension

Type of Posting	Revision Bulletin
Posting Date	27-Sep-2024
Official Date	1-Oct-2024
Expert Committee	Small Molecules 4

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 4 Expert Committee has revised the Oxcarbazepine Oral Suspension monograph. The purpose of this revision is to add *Dissolution Test 4* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). Existing references to reagents and reagent names have been updated for consistency with official reagent entry names. This revision also necessitates a change in the table numbering in the test for *Organic Impurities*.

- *Dissolution Test 4* was validated using the Zorbax SB-phenyl brand of column with L11 packing. The typical retention time for oxcarbazepine is about 5.5 min.

The Oxcarbazepine Oral Suspension Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Yanyin Yang, Senior Scientist II (301-692-3623 or yanyin.yang@usp.org).